Literature DB >> 3114567

Peripheral blood adherent cells from AIDS patients inhibit normal T-colony growth through decreased expression of interleukin 2-receptors and production of interleukin 2.

Y Lunardi-Iskandar, V Georgoulias, D Vittecoq, M T Nugeyre, A Ammar, C Clemenceau, F Barre-Sinoussi, J C Chermann, L Schwartzenberg, C Jasmin.   

Abstract

Adherent cells display an important accessory role on normal T-cell colony formation. Since the in-vitro proliferation of T colony-forming cells (T-CFC) from AIDS patients is extremely impaired we studied the effect of patients' adherent cells on T-CFC growth. Patients' peripheral blood mononuclear cells (PBMC) were fractionated on the basis of rosette formation with sheep red blood cells and complement-mediated cytotoxicity with OKT3 monoclonal antibody (E-T3-). Both mature (E+) T cells and E-OKT3- cell fractions failed to generate T-cell colonies although colony growth could be obtained from unfractionated PBMC. In five out of 12 AIDS patients, adherent cell-depletion of PBMC enhanced the plating efficiency. Moreover, patients' but not normal adherent cells could inhibit normal T-cell colony growth in a dose-dependent manner. Media conditioned by patients' unstimulated adherent cells (LCM-A+p) also inhibit normal T-cell colony formation. In addition, LCM-A+p were capable of inhibiting interleukin 2-receptor (IL2-R) expression and interleukin 2 (IL2) production by normal mitogen-stimulated T cells. These LCM-A+p did not contain detectable reverse transcriptase activity nor could they infect the CEM T-cell line which is permissive to human immunodeficiency virus (HIV). Conversely, this adherent cell-derived inhibitory activity could be abrogated by heating or treatment with proteolytic enzymes. These findings indicate that the low T-cell colony formation in some AIDS patients could be due to adherent cell-derived inhibitory activity(ies).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114567     DOI: 10.1016/0145-2126(87)90013-0

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

1.  Effect of phorbol myristate acetate on T cell colony formation, interleukin-2 (IL-2) receptor expression and IL-2 production by cells from patients at all stages of HIV infection.

Authors:  M Allouche; Y Lunardi-Iskandar; C Varela-Millot; M Itzhaki; P Cornuet; P Meyer; C Jasmin; V Georgoulias
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

2.  Replication of the human immunodeficiency virus 1 and impaired differentiation of T cells after in vitro infection of bone marrow immature T cells.

Authors:  Y Lunardi-Iskandar; M T Nugeyre; V Georgoulias; F Barré-Sinoussi; C Jasmin; J C Chermann
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

Review 3.  Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions.

Authors:  N Chirmule; S Pahwa
Journal:  Microbiol Rev       Date:  1996-06

4.  Biological and biochemical characterization of a factor produced spontaneously by adherent cells of human immunodeficiency virus-infected patients inhibiting interleukin-2 receptor alpha chain (Tac) expression on normal T cells.

Authors:  A Ammar; C Cibert; A M Bertoli; V Tsilivakos; C Jasmin; V Georgoulias
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

5.  Human immunodeficiency virus-infected adherent cell-derived inhibitory factor (p29) inhibits normal T cell proliferation through decreased expression of high affinity interleukin-2 receptors and production of interleukin-2.

Authors:  A Ammar; Y Sahraoui; A Tsapis; A M Bertoli; C Jasmin; V Georgoulias
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

6.  Abnormal in vitro proliferation and differentiation of T cell colony-forming cells in patients with tropical spastic paraparesis/human T lymphocyte virus type I (HTLV-I)-associated myeloencephalopathy and healthy HTLV-I carriers.

Authors:  Y Lunardi-Iskandar; A Gessain; V H Lam; R C Gallo
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.